Handa Pharmaceuticals Inc. (6620.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan

Price
124.00 TWD
Market cap
20.90 bn TWD
P/E (2025)
27.87
P/S (2025)
12.08
Dividend yield
1.67 %
Net margin
43.36 %
Return on equity (ROE)
13.25 %
Return on assets (ROA)
12.72 %

Handa Pharmaceuticals Inc. financials

Fiscal year20242025
Revenue830.67 m TWD1.73 bn TWD
Gross profit829.50 m TWD1.46 bn TWD
Operating income418.06 m TWD934.18 m TWD
EBIT479.66 m TWD939.18 m TWD
Net income472.74 m TWD749.77 m TWD
Diluted EPS – continuing operations3.37 TWD4.45 TWD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Handa Pharmaceuticals Inc.

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Phyrago, an oral kinase inhibitor used to treat chronic myeloid leukemia and acute lymphoblastic leukemia; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; Varenicline tablet and HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.